Connect with us

BUSINESS

Dr. Reddy’s to introduce Sanofi’s novel RSV drug in India 

Published

on

Dr. Reddy’s to introduce Sanofi’s novel RSV drug in India 


Dr. Reddy’s Laboratories will expand its partnership with Sanofi Healthcare India (SHIPL) by launching the latter’s novel drug Beyfortus (nirsevimab) in India.

Containing monoclonal antibody nirsevimab in a prefilled injection, Beyfortus is used for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season.

Dr. Reddy’s will get exclusive rights from SHIPL to promote and distribute Beyfortus. The announcement follows an exclusive distribution partnership it had forged for Sanofi portfolio of vaccines in India last year. Beyfortus is expected to be launched in the second quarter of the current fiscal year, the Hyderabad-based pharma major said.

RSV is a highly contagious virus that can lead to serious respiratory illness for infants. In addition to being the most common cause of LRTD such as bronchiolitis and pneumonia in infants, it is also a leading cause of hospitalisation in infants worldwide, with most hospitalisations occurring in healthy infants born at term. In 2019, there were approximately 33 million cases of acute lower respiratory infections globally, leading to more than 3 million hospitalisations, and it was estimated that there were 26,300 in-hospital deaths of children younger than 5 years, Dr.Reddy’s said in a release.

Launch of Beyfortus will help strengthen its immunisation portfolio in India, CEO-Branded Markets (India and Emerging Markets) M.V. Ramana said.

Beyfortus, which has been approved for use in the EU, the U.S., China, Japan and many other countries, received marketing authorisation approval in India from the Central Drugs Standard Control Organization (CDSCO) in June.

“In India, where the disease burden is significant and early protection is critical, this collaboration with Dr. Reddy’s enables us to reach parents and healthcare providers with an innovative solution,” Head of Sanofi Vaccines (India) Nitya Padmanabhan said.



Source link

Continue Reading
Comments

BUSINESS

Urban Company files for Rs 1,900 crore IPO with Sebi – Times of India

Published

on

Urban Company files for Rs 1,900 crore IPO with Sebi – Times of India


Urban Company files draft papers for IPO

NEW DELHI: Urban Company has filed draft papers with the Securities and Exchange Board of India (Sebi) for an initial public offering (IPO) to raise Rs 1,900 crore. According to its Draft Red Herring Prospectus (DRHP), the IPO will comprise a fresh issue of shares worth Rs 429 crore and an offer for sale (OFS) of shares worth Rs 1,471 crore by existing investors.
Key OFS participants include Accel India, Elevation Capital, Bessemer India Capital Holdings II Ltd, Internet Fund V Pte. Ltd, and VYC11 Ltd.
The company plans to utilise the proceeds to fund technological upgrades and cloud infrastructure (Rs 190 crore), lease payments for new office spaces (Rs 70 crore), marketing initiatives (Rs 80 crore), and for general corporate purposes.
Kotak Mahindra Capital Company, Morgan Stanley India Company, Goldman Sachs (India) Securities, and JM Financial are acting as the book-running lead managers for the IPO.
Urban Company operates a technology-driven online marketplace offering home and beauty services. As of December 31, 2024, it had a presence in 59 cities across India, the United Arab Emirates, Singapore, and Saudi Arabia, including 48 locations within India.
The platform enables consumers to book a wide range of services such as cleaning, pest control, electrical and plumbing work, carpentry, appliance servicing and repair, painting, skincare, hair grooming, and massage therapy, with services delivered by independent professionals.





Source link

Continue Reading

BUSINESS

Central Bank of India net profit rises 28%

Published

on

Dr. Reddy’s to introduce Sanofi’s novel RSV drug in India 


Central Bank of India Q4 net profit increased 28% to ₹ 1,034 crore from ₹807 crore in the year-ago period. The company’s net interest income, however, contracted 4% to ₹3,399 crore in the reporting quarter. The net interest margin also dipped to 3.17% in the quarter ended March 2025, as against 3.6% in the corresponding period last fiscal. The gross NPAs improved to 3.2% and net NPA to 0.5% from 4.5% and 1.2% respectively. The bank expanded net profit by 48.5% to ₹3,785 crore in fiscal 2024-25 from ₹2,549 crore in FY24.



Source link

Continue Reading

BUSINESS

IIP grows 3% as electricity, manufacturing output surge

Published

on

IIP grows 3% as electricity, manufacturing output surge


The Index of Industrial Production (IIP) grew 3% as electricity and manufacturing sector production surged in March 2025, according to data from the Ministry of Commerce and Industry. The number was lower than the Reuters estimate of 3.3%.

Electricity production surged 2.7 percentage points to 6.3% in the month under review as summers have increased power demand. Manufacturing sector output grew at a quicker 3% in March 2025, as against 2.7% in the previous month. Mining and quarrying sector growth slowed to 0.4% in March as against 1.6% in February.

In the use-based classification, consumer durables and construction registered the sharpest increase in growth, coming at 6.6% and 8.8% respectively. These sectors grew at 3.7% and 6.8% respectively in February.

The other sectors where output grew at a faster pace than February were primary sectors and intermediate goods, which grew at 3.1% and 2.3% respectively.  Consumer non-durables output continued to contract for the second quarter, shrinking a steeper 4.7% in the month under review. Growth in capital goods output increased at a slower 2.4% in March, compared with 8.1% in the month before. 

On a year-on-year basis, IIP growth came in at 4%, making it the slowest in four years. Growth in output of all three sectors by economic activity slowed in the year-ended March 2025. In use-based classification, all sectors registered a slower growth. Consumer durables output increased 8% in 2024-25 from 3% in the previous year, but  this was offset by consumer non-durables where production shrank for the first time in four years, declining 1.6%.

Industrial growth though has domestic tailwinds will also face global headwinds, say experts.



Source link

Continue Reading

Trending

Copyright © 2025 Republic Diary. All rights reserved.